Unknown

Dataset Information

0

DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.


ABSTRACT: PEGylated liposomes have transformed chemotherapeutic use of doxorubicin by reducing its cardiotoxicity; however, it remains unclear whether liposomal doxorubicin is therapeutically superior to free doxorubicin. Here, we demonstrate a novel PEGylated liposome system, named DAFODIL (Doxorubicin And 5-Flurouracil Optimally Delivered In a Liposome) that inarguably offers superior therapeutic efficacies compared to free drug administrations. Delivery of synergistic ratios of this drug pair led to greater than 90% reduction in tumor growth of murine 4T1 mammary carcinoma in vivo. By exploiting synergistic ratios, the effect was achieved at remarkably low doses, far below the maximum tolerable drug doses. Our approach re-invents the use of liposomes for multi-drug delivery by providing a chemotherapy vehicle which can both reduce toxicity and improve therapeutic efficacy. This methodology is made feasible by the extension of the ammonium-sulfate gradient encapsulation method to nucleobase analogues, a liposomal entrapment method once conceived useful only for anthracyclines. Therefore, our strategy can be utilized to efficiently evaluate various chemotherapy combinations in an effort to translate more effective combinations into the clinic.

SUBMITTER: Camacho KM 

PROVIDER: S-EPMC5289372 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.

Camacho Kathryn M KM   Menegatti Stefano S   Vogus Douglas R DR   Pusuluri Anusha A   Fuchs Zoë Z   Jarvis Maria M   Zakrewsky Michael M   Evans Michael A MA   Chen Renwei R   Mitragotri Samir S  

Journal of controlled release : official journal of the Controlled Release Society 20160324


PEGylated liposomes have transformed chemotherapeutic use of doxorubicin by reducing its cardiotoxicity; however, it remains unclear whether liposomal doxorubicin is therapeutically superior to free doxorubicin. Here, we demonstrate a novel PEGylated liposome system, named DAFODIL (Doxorubicin And 5-Flurouracil Optimally Delivered In a Liposome) that inarguably offers superior therapeutic efficacies compared to free drug administrations. Delivery of synergistic ratios of this drug pair led to gr  ...[more]

Similar Datasets

| S-EPMC3657616 | biostudies-literature
| S-EPMC9461478 | biostudies-literature
| S-EPMC6966652 | biostudies-literature
| S-EPMC8221259 | biostudies-literature
| S-EPMC3770687 | biostudies-literature
| S-EPMC3148779 | biostudies-literature
| S-EPMC6058606 | biostudies-literature
| S-EPMC4018157 | biostudies-literature
| S-EPMC6101145 | biostudies-literature
| S-EPMC4722080 | biostudies-literature